University of Illinois at Chicago
Browse

Going Past the Data for Temozolomide

Download (60.01 kB)
journal contribution
posted on 2012-06-27, 00:00 authored by J. Lee Villano, Nathalie Letarte, Linda R. Bressler
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences on length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

History

Publisher Statement

© 2012 by Springer Verlag, Cancer Chemotherapy and Pharmacology The original publication is available at www.springerlink.com DOI: 10.1007/s00280-011-1796-4

Publisher

Springer Verlag

Language

  • en_US

issn

0344-5704

Issue date

2012-04-01

Usage metrics

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC